Cystatin C, Training, and Exercise: What Athletes and Longevity Patients Need to Know

What Is Cystatin C and Why Does It Matter for Physically Active Adults?

Cystatin C is a cysteine protease inhibitor encoded by the CST3 gene, produced at a steady rate by virtually every nucleated cell in the body. Because production does not depend on muscle mass or dietary protein, it behaves very differently from creatinine when interpreting kidney function in athletes, resistance-trained adults, or anyone using GLP-1 agonists, TRT, or peptide protocols that shift body composition.

The Core Measurement Problem with Creatinine in Athletes

Creatinine is a breakdown product of creatine phosphate in muscle. An athlete with 85 kg of lean mass produces far more creatinine per day than a sedentary adult, which pushes serum creatinine upward and makes creatinine-based eGFR appear falsely normal or even supranormal. A 2018 study published in the Clinical Journal of the American Society of Nephrology documented that creatinine-based CKD-EPI equations overestimated measured GFR by a median of 14 mL/min/1.73 m² in competitive athletes compared with Cystatin C-based equations (1).

Why Cystatin C Is More Muscle-Mass Independent

Cystatin C is filtered freely at the glomerulus, then reabsorbed and catabolized by proximal tubular cells. The serum level reflects primarily how fast the kidney clears it, not how much muscle the patient carries. KDIGO's 2024 Clinical Practice Guideline Update for CKD explicitly recommends adding Cystatin C-based eGFR when creatinine-based estimates are uncertain, including in patients with "atypical muscle mass" (2).

A combined CKD-EPI creatinine-cystatin C equation is now considered the most accurate routinely available GFR estimate without a formal clearance study (2).

Cystatin C Normal Range and Optimal Targets

Most certified clinical laboratories report a reference interval of 0.62 to 1.15 mg/L for adults. That range was derived from mixed-population cohorts and includes people with subclinical kidney decline.

Standard vs. Optimal Ranges

"Normal" and "optimal" are not the same number. The standard reference interval marks where roughly 95% of a reference population falls. Longevity medicine looks at where low-risk outcomes concentrate.

In the Cardiovascular Health Study (N = 4,637 adults aged 65 and older), each 0.1 mg/L increment above 1.0 mg/L was associated with a 9% higher risk of incident cardiovascular disease and a 7% higher all-cause mortality risk (3). Levels at or below 0.9 mg/L tracked with the lowest-risk tertile in that cohort.

Separately, the ARIC study (N = 11,143) showed Cystatin C outperformed creatinine in predicting CKD progression and cardiovascular events at values still within "normal" creatinine ranges (4). This is why longevity-focused clinicians at HealthRX target Cystatin C below 0.9 mg/L rather than simply "within reference range."

Sex, Age, and Ethnicity Adjustments

Cystatin C rises modestly with age, approximately 0.004 to 0.006 mg/L per year after age 40. Unlike creatinine, it shows only minor sex differences (males average about 0.04 mg/L higher than females). Ethnicity-based correction factors are not recommended for Cystatin C by current KDIGO guidance, one of its practical advantages over creatinine-based equations (2).

How Acute Exercise Affects Cystatin C

A single bout of intense aerobic or resistance exercise can raise Cystatin C measurably. This is one of the most practically important facts for any clinician ordering this test in an active patient.

Magnitude and Time Course of the Acute Rise

A 2010 study in Nephrology Dialysis Transplantation (N = 20 trained cyclists) found that Cystatin C rose by a mean of 18% at 2 hours post-maximal cycle ergometer test, then returned to baseline within 24 hours (5). The authors proposed two mechanisms: reduced GFR during intense exercise due to renal vasoconstriction, and possible increased catabolism-related release of the protein from exercising cells.

A 2014 meta-analysis of 11 studies (N = 324 participants) confirmed the transient post-exercise rise pattern. Mean peak increase was 15.3% (95% CI: 11.8 to 18.8%), with most studies showing full normalization by 24 to 48 hours (6).

Resistance Training vs. Aerobic Exercise

Resistance training bouts appear to produce a smaller acute Cystatin C spike compared with maximal aerobic efforts. A controlled study comparing 1-repetition-maximum testing against VO2max cycling found the resistance protocol raised Cystatin C by 8% vs. 19% for the aerobic protocol at the 2-hour mark (5). The clinical implication: a blood draw taken two hours after a heavy squat session may still modestly overestimate the true steady-state value.

Practical Sampling Guidance

Collect Cystatin C blood samples at least 24 to 48 hours after any intense training session. For patients running ultra-endurance events, 72 hours may be more appropriate. This timing window eliminates the transient exercise artifact and gives a result that reflects true resting GFR. For routine monitoring on TRT, peptide protocols, or GLP-1 therapy, instruct patients to skip their morning workout before the blood draw.

How Chronic Training Affects Cystatin C

The acute and chronic effects of exercise point in different directions, which confuses many patients who see a higher-than-expected Cystatin C on their first post-workout panel.

Aerobic Fitness and Resting Cystatin C

Well-designed longitudinal data show aerobic fitness is associated with lower or stable resting Cystatin C. In the Cooper Center Longitudinal Study (N = 2,450 adults followed for a median of 25 years), higher cardiorespiratory fitness (CRF) quartile at baseline was associated with significantly lower Cystatin C at follow-up, with the highest-fit men averaging 0.83 mg/L vs. 0.99 mg/L in the lowest-fit quartile (7). Better renal perfusion at rest, reduced systemic inflammation (C-reactive protein and IL-6 both decline with training), and improved blood pressure control all likely contribute.

Resistance Training and Cystatin C Over Time

Chronic resistance training presents a more nuanced picture. Because muscle mass does not drive Cystatin C production, heavy resistance athletes do not see the same creatinine-versus-Cystatin C divergence as a problem for Cystatin C specifically. However, a 12-week progressive resistance program in 58 older adults (mean age 68) produced no statistically significant change in Cystatin C despite meaningful gains in lean mass (P = 0.31 for Cystatin C change), confirming the marker's independence from muscle hypertrophy (8).

High-Volume Endurance Athletes: A Special Case

Elite endurance athletes (marathon runners, triathletes, cyclists) sometimes show chronically lower Cystatin C compared with matched sedentary controls, likely reflecting true supranormal GFR ("hyperfiltration reserve"). Whether chronic hyperfiltration is beneficial, benign, or mildly harmful over decades remains an open research question. Current evidence does not support kidney damage from habitual endurance training in the absence of NSAID overuse, dehydration, or pre-existing CKD.

The HealthRX clinical framework for interpreting Cystatin C in active patients uses a three-tier classification:

| Tier | Resting Cystatin C | Clinical Action | |---|---|---| | Optimal | <0.90 mg/L | No intervention; continue monitoring annually | | Borderline | 0.90 to 1.10 mg/L | Recheck in 3 months; optimize hydration, blood pressure, HbA1c | | Elevated | >1.10 mg/L | Add eGFR creatinine-cystatin C combined; nephrology consult if below 60 mL/min/1.73 m² |

All values assume sample collected at least 24 to 48 hours after intense exercise and euthyroid status confirmed.

Cystatin C on TRT, GLP-1, and Peptide Protocols

Body composition shifts rapidly on hormonal and metabolic therapies. This is where Cystatin C's independence from muscle mass becomes a direct patient-safety issue.

TRT and Lean Mass Gains

Testosterone replacement therapy reliably increases lean body mass, often by 3 to 5 kg in the first six months (9). This rise in muscle bulk inflates creatinine, making creatinine-based eGFR look stable or improved even when true GFR is unchanged or declining. A patient on TRT who also has early diabetic nephropathy could be falsely reassured by a "normal" creatinine-based eGFR. Cystatin C closes that diagnostic gap.

GLP-1 Receptor Agonists and Kidney Protection

Semaglutide has demonstrated kidney-protective effects in people with type 2 diabetes and CKD. In the FLOW trial (N = 3,533), semaglutide 1.0 mg weekly reduced the risk of a composite kidney endpoint by 24% vs. Placebo (HR 0.76, 95% CI 0.66 to 0.88, P<0.001) (10). Monitoring Cystatin C in GLP-1 patients is useful because the weight loss these agents produce reduces both muscle mass and adiposity, which can unpredictably shift creatinine while Cystatin C tracks actual filtration.

Thyroid Hormones: The Non-Exercise Confounder

Thyroid status independently regulates Cystatin C production. Hypothyroidism raises Cystatin C by 10 to 30% without any change in true GFR, mimicking kidney decline (11). Any patient with a TSH above 4.5 mIU/L should have thyroid function corrected before Cystatin C is used to estimate GFR. This applies to patients on compounded T4/T3 combinations or those with undiagnosed subclinical hypothyroidism.

Calculating eGFR from Cystatin C: Which Equation to Use

Several equations exist. Choosing the right one changes clinical classification.

CKD-EPI Cystatin C 2021 Equation

The 2021 CKD-EPI Cystatin C equation (race-free) is the current standard endorsed by KDIGO and by the National Kidney Foundation-American Society of Nephrology (NKF-ASN) Task Force (12). It uses serum Cystatin C, age, and sex. The NKF-ASN Task Force stated: "The CKD-EPI 2021 equations for eGFRcr, eGFRcys, and eGFRcr-cys do not include a race variable, thereby addressing concerns about the use of race in estimating kidney function." (12)

Combined Creatinine-Cystatin C Equation

When both creatinine and Cystatin C are available, the combined CKD-EPI creatinine-cystatin C 2021 equation reduces bias and improves precision compared with either alone. KDIGO 2024 recommends confirming CKD staging with the combined equation when the creatinine-only eGFR falls in a borderline range (45 to 75 mL/min/1.73 m²) (2).

Practical Ordering Note

Order both serum creatinine and serum Cystatin C on the same tube draw. Most automated analyzers report Cystatin C via particle-enhanced immunoturbidimetric assay (PETIA) or immunonephelometry. Lab-to-lab variability is lower than for creatinine but still exists; standardize to the same laboratory for longitudinal tracking.

Cystatin C as a Longevity Biomarker

Beyond kidney function, Cystatin C has earned attention as a general aging biomarker.

Cardiovascular and All-Cause Mortality Prediction

The CHS Collaborative Research Group found that Cystatin C above 1.29 mg/L (top quartile in their elderly cohort) was associated with a 2.6-fold higher risk of heart failure hospitalization compared with the bottom quartile (Cystatin C below 0.86 mg/L), after adjusting for traditional risk factors (3). This association persisted after adjusting for creatinine-based eGFR, suggesting Cystatin C captures cardiovascular risk beyond kidney filtration alone.

Cognitive Decline

A prospective analysis in the Health ABC Study (N = 2,805 adults aged 70 to 79) found that each 0.1 mg/L higher Cystatin C at baseline was associated with a 14% higher odds of cognitive decline over 5 years (13). The mechanism may involve cerebral small-vessel disease mediated by the same endothelial dysfunction that impairs glomerular filtration.

Physical Performance

In the InCHIANTI study (N = 1,016 community-dwelling adults), higher Cystatin C independently predicted slower gait speed and lower grip strength over a 6-year follow-up, even after adjusting for age, comorbidities, and creatinine-based GFR (14). This makes Cystatin C one of the few biomarkers that connects kidney function, cardiovascular risk, and physical performance in a single measurement.

As Dr. Lesley Inker, a lead author on the 2021 NKF-ASN CKD-EPI equation paper, noted in NEJM: "Cystatin C, measured in addition to creatinine, could identify an additional 1.2 million U.S. Adults with CKD who would otherwise be classified as having normal kidney function by creatinine alone." (12)

Clinical Protocol for Monitoring Cystatin C in Exercising Adults

Testing Frequency

• Baseline: Order Cystatin C at program entry for all patients on TRT, GLP-1 agonists, peptide protocols, or those with cardiovascular risk factors.
• Follow-up: Recheck at 3 months after any new therapy, then annually if stable and below 0.9 mg/L.
• Trigger recheck: Any creatinine rise of 0.2 mg/dL or more, new hypertension, new diabetes diagnosis, or athlete pre-season screen.

Interpreting a Rising Cystatin C

A confirmed rise of 0.15 mg/L or more over 12 months (after ruling out acute exercise artifact and thyroid dysfunction) warrants:

1. Repeat Cystatin C plus creatinine with combined eGFR calculation.
2. Urine albumin-to-creatinine ratio (UACR) to detect early tubular or glomerular injury.
3. Blood pressure optimization to under 130/80 mmHg per AHA/ACC 2017 guidelines (15).
4. Review of nephrotoxic exposures: NSAIDs, high-dose creatine (evidence for harm is weak but elimination is low risk), contrast agents.

Exercise Prescription When Cystatin C Is Elevated

Patients with Cystatin C between 0.9 and 1.15 mg/L should not be told to avoid exercise. The opposite is more appropriate. Moderate aerobic activity (150 minutes per week at 50 to 70% VO2max) is associated with slower CKD progression per a systematic review of 13 RCTs published in the American Journal of Kidney Diseases (16). High-impact contact sports and extreme dehydration events deserve more caution in patients with confirmed eGFR below 45 mL/min/1.73 m².